Sensei Biotherapeutics (NASDAQ:SNSE) Now Covered by Leerink Partners

Leerink Partners assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a research report report published on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $50.00 price objective on the stock.

Several other research analysts also recently issued reports on SNSE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday, December 29th. Wall Street Zen raised Sensei Biotherapeutics to a “hold” rating in a research note on Saturday, December 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Sensei Biotherapeutics Price Performance

SNSE opened at $31.39 on Monday. The stock has a market cap of $42.06 million, a P/E ratio of -1.88 and a beta of -0.10. The stock’s 50 day simple moving average is $27.89 and its 200 day simple moving average is $16.18. Sensei Biotherapeutics has a 1-year low of $5.25 and a 1-year high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Monday, March 30th. The company reported ($3.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.81) by $1.07.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.